75 related articles for article (PubMed ID: 35767923)
21. Treatment at Twilight: An Analysis of Therapy Patterns and Outcomes in Adults 80 Years and Older With Advanced or Metastatic NSCLC.
Burns EA; Chen WH; Mathur S; Kieser RB; Zhang J; Bernicker EH
JTO Clin Res Rep; 2023 Oct; 4(10):100570. PubMed ID: 37822698
[TBL] [Abstract][Full Text] [Related]
22. Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer.
Onn A; Gottfried T; Stemmer A; Appel S; Lawrence YR; Urban D; Beller T; Daher S; Bar J
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199805
[TBL] [Abstract][Full Text] [Related]
23. Too Much of a Good Thing: The Association of Elevated Vitamin B12 Levels and Outcomes in Patients With Cancer Treated With Immunotherapy.
Turgeman I; Benaim AR; Regev-Tsur S; Turgeman S; Abu Amna M; Badran O; Bar-Sela G
J Immunother; 2024 May; 47(4):117-122. PubMed ID: 37909180
[TBL] [Abstract][Full Text] [Related]
24. Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma-Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation.
Duwe G; Müller L; Ruckes C; Fischer ND; Frey LJ; Börner JH; Rölz N; Haack M; Sparwasser P; Jorg T; Neumann CCM; Tsaur I; Höfner T; Haferkamp A; Hahn F; Mager R; Brandt MP
Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760923
[TBL] [Abstract][Full Text] [Related]
25. Improved estimation of overall survival and progression-free survival for state transition modeling.
Wigfield PC; Heeg B; Ouwens M
J Comp Eff Res; 2024 Jan; 13(1):e230031. PubMed ID: 38099516
[No Abstract] [Full Text] [Related]
26. Research in interventional oncology: How sound is the evidence base?
Kaufmann NC; Zeka B; Pereira PL
J Med Imaging Radiat Oncol; 2023 Dec; 67(8):903-914. PubMed ID: 37170844
[TBL] [Abstract][Full Text] [Related]
27. Welcoming protocols.io.
Nat Protoc; 2024 May; ():. PubMed ID: 38760509
[No Abstract] [Full Text] [Related]
28. Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Frost N; Bleckmann A; Griesinger F; Grohé C; Janning M; Kollmeier J; Reinmuth N; Sebastian M; Thomas M; Reck M
Clin Lung Cancer; 2023 Sep; 24(6):568-572. PubMed ID: 37169628
[TBL] [Abstract][Full Text] [Related]
29. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Waser NA; Quintana M; Schweikert B; Chaft JE; Berry L; Adam A; Vo L; Penrod JR; Fiore J; Berry DA; Goring S
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38521542
[TBL] [Abstract][Full Text] [Related]
30. Trial Design for Cancer Immunotherapy: A Methodological Toolkit.
Saad ED; Coart E; Deltuvaite-Thomas V; Garcia-Barrado L; Burzykowski T; Buyse M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760636
[TBL] [Abstract][Full Text] [Related]
31. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
Zhang Z; Pan Q; Lu M; Zhao B
EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482
[TBL] [Abstract][Full Text] [Related]
32. A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.
Liu H; Milenković-Grišić AM; Krishnan SM; Jönsson S; Friberg LE; Girard P; Venkatakrishnan K; Vugmeyster Y; Khandelwal A; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1738-1750. PubMed ID: 37165943
[TBL] [Abstract][Full Text] [Related]
33. Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making.
Turner DC; Wada R; Zhou H; Wang X; de Greef R; Valiathan C; Zhang L; Zhang N; Kuchimanchi M; Chen TT; Ballas M; Visser SAG
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1751-1763. PubMed ID: 36642813
[TBL] [Abstract][Full Text] [Related]
34. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
[TBL] [Abstract][Full Text] [Related]
35. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
36. Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
Li L; Xu F; Chen Y; Ren X; Liu Y; Chen Y; Xia S
BMJ Open; 2020 Nov; 10(11):e034010. PubMed ID: 33444168
[TBL] [Abstract][Full Text] [Related]
37. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
38. Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis.
Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Tilki D; Shariat SF; Gallucci M; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
Crit Rev Oncol Hematol; 2022 Jan; 169():103534. PubMed ID: 34823022
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
